Clinical Trial Search

Primary: Latency to Persistent Sleep After Middle-of-the-Night Awakening as Measured by Polysomnography — 9.69; 16.89; 28.12 minutes — p=<0.001

Primary: Latency to Sleep Onset After Middle-of-the-Night Awakening at Baseline — 68.13; 69.42 minutes

Primary: Adjusted (LS) Mean Change From Baseline in Wrinkle Severity Rating Scale (SRS) Score of Each Nasolabial Fold (NLF) as Determined by the Blinded Evaluator at Week 12…

Primary: Comparison of Proportion of Virologic Response at Week 48 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population — 384; 409; 122; 96…

Primary: Change in the Number of Moderate to Severe Headache Days Within a 28 Day Average Period in Six Months Compared to Baseline — 4.4; 4.7 Moderate to severe headache days…

Primary: Change From Baseline in Knee Pain Over the Course of the 26-week Initial Treatment Period As Measured by Participants Using the Western Ontario and McMaster Universities…

Primary: Overall Survival — 12.1; 10.1 months

Primary: Clinical Disease Activity Index (CDAI) Remission (≤2.8) at Both Week 20 and Week 24 — 18.8; 6.1 percentage of subjects

Primary: Occurrence of Treatment-emergent Adverse Events During the Study Period (Until the Time of Approval Granted) — 381 participants

Primary: Number of All Hemorrhages — 3 Hemorrhages

Primary: Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event — 22; 112 participants

Primary: The Post Dose Strain-specific Serum Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMTs) in the Q/LAIV-BFS (MEDI8662) Arm as Compared to Those in the…

Primary: Resolution of Anterior Chamber Cells. — 64; 28 participants

Primary: Mean Change in Baseline Observation Carried Forward (BOCF) Average Daily Pain Score — -2.12; -1.63 Scores on a scale — p=0.0125

Primary: Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing — 68; 31; 23; 14 participants